People With CHC Who Achieved a Sustained Virological Response Following Therapy With Direct Acting Antiviral Agents

PHASE4Active, not recruitingINTERVENTIONAL

Enrollment

121

Participants

Timeline

Start Date

October 19, 2018

Primary Completion Date

December 31, 2032

Study Completion Date

December 31, 2032

Conditions

Diabetes MellitusHepatitis C, ChronicCardiovascular Diseases

Interventions

DRUG

Epclusa

sofosbuvir/velapatasvir combination (Epclusa)

Trial Locations (1)

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors

lead

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH